{
  "id": "6278e49256bf9aee6f000017",
  "type": "list",
  "question": "For what known mutations is KRAS gene considered to be oncogenic?",
  "ideal_answer": "G12C, G12V, G12D and G12A are all observed mutations of the KRAS oncogene.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25941399",
    "http://www.ncbi.nlm.nih.gov/pubmed/25359494",
    "http://www.ncbi.nlm.nih.gov/pubmed/31289513",
    "http://www.ncbi.nlm.nih.gov/pubmed/25257576",
    "http://www.ncbi.nlm.nih.gov/pubmed/22247021",
    "http://www.ncbi.nlm.nih.gov/pubmed/26970110",
    "http://www.ncbi.nlm.nih.gov/pubmed/31309326",
    "http://www.ncbi.nlm.nih.gov/pubmed/31332011",
    "http://www.ncbi.nlm.nih.gov/pubmed/29453361",
    "http://www.ncbi.nlm.nih.gov/pubmed/20034871",
    "http://www.ncbi.nlm.nih.gov/pubmed/33618059",
    "http://www.ncbi.nlm.nih.gov/pubmed/20385028",
    "http://www.ncbi.nlm.nih.gov/pubmed/33709341",
    "http://www.ncbi.nlm.nih.gov/pubmed/33325140",
    "http://www.ncbi.nlm.nih.gov/pubmed/23572025",
    "http://www.ncbi.nlm.nih.gov/pubmed/22232209",
    "http://www.ncbi.nlm.nih.gov/pubmed/30199525",
    "http://www.ncbi.nlm.nih.gov/pubmed/31827279",
    "http://www.ncbi.nlm.nih.gov/pubmed/22329297",
    "http://www.ncbi.nlm.nih.gov/pubmed/20846262",
    "http://www.ncbi.nlm.nih.gov/pubmed/32956987",
    "http://www.ncbi.nlm.nih.gov/pubmed/25065594",
    "http://www.ncbi.nlm.nih.gov/pubmed/32176377",
    "http://www.ncbi.nlm.nih.gov/pubmed/34369256",
    "http://www.ncbi.nlm.nih.gov/pubmed/29650325",
    "http://www.ncbi.nlm.nih.gov/pubmed/9612526",
    "http://www.ncbi.nlm.nih.gov/pubmed/33860195",
    "http://www.ncbi.nlm.nih.gov/pubmed/11668624",
    "http://www.ncbi.nlm.nih.gov/pubmed/34822010",
    "http://www.ncbi.nlm.nih.gov/pubmed/26701267",
    "http://www.ncbi.nlm.nih.gov/pubmed/32308773",
    "http://www.ncbi.nlm.nih.gov/pubmed/19440799"
  ],
  "snippets": [
    {
      "text": "Mutations in KRAS - such as the G12C mutation - are found in most pancreatic, half of colorectal and a third of lung cancer cases and is thus responsible for a substantial proportion of cancer deaths",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32176377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "KRAS G12V mutation upregulates PD-L1 expression via TGF-\u03b2/EMT signaling pathway in human non-small-cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33325140",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The most prevalent mutant subtype of KRAS in lung adenocarcinoma was G12C(9.88 %,56/567), followed by G12\u2009V(5.82 %,33/567), G12D(3.00 %,17/567), G12A(3.00 %,17/567), respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32956987",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Over 80% of oncogenic KRAS mutations occur at codon 12, where the glycine residue is substituted by different amino acids, leading to genomic heterogeneity of KRas-mutant tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33618059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "KRAS codon 146 mutations, as well as the previously reported OES-associated alterations, are known oncogenic KRAS mutations with distinct functional consequences.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26970110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Because oncogenic mutations occur in exons 2 or 3, two constitutively active KRAS proteins-each capable of transforming cells-are encoded when KRAS is activated by mutation2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31827279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " KRAS mutational status was determined in the purified DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13As",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The majority of mutations are found at KRAS codons 12 and 13, and they appear to be more frequent in smokers and adenocarcinoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20034871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To test this hypothesis, we analyzed 66 anal, vulvar, and head and neck SCC with known immunohistochemical p16(INK4a) and HPV DNA status for KRAS mutations in exon 2 (codons 12, 13, and 15)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25257576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "6%) KRAS mutations in exon 1 (nine in codon 12 and one in codon 13), two missense mutations of BRAF (6%), one within exon 11 (G469A), and one V600E hot spot mutation in exon 15 of BRAF",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19440799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "21); (3) KRAS(G12) and KRAS(G13) mutations are correlated, respectively, with the left and right colon cancer development (P<0.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23572025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26701267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp.RESULTS: We found no evidence of KRAS oncogenic mutations in all analyzed tumors.CONCLUSIONS: This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similarly, the most frequent KRAS oncogenic mutation G12D also drives K-RAS4B toward an exposed configuration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Traditionally, the oncogenic properties of KRAS missense mutants at position 12 (G12X) have been considered as equal.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30199525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The findings provide a basis to understand better the oncogenic properties of KRAS G12X mutants and the consequences of the observed nonrandom frequencies of specific G12X mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30199525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition to testing for known actionable oncogenic driver alterations in EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, RET, and NTRK and for the expression of programmed cell-death protein ligand 1, pathologists, medical oncologists, and community practitioners will need to incorporate routine testing for emerging biomarkers such as MET amplification, ERBB2 (alias HER2), and KRAS mutations, particularly KRAS G12C, considering the promising development of direct inhibitors of KRasG12C protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33618059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The KRAS glycine-to-cysteine mutation (G12C) composes approximately 44% of KRAS mutations in non-small cell lung cancer, with mutant KRasG12C present in approximately 13% of all patients with lung adenocarcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33618059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1 is mechanistically distinct from covalent KRASG12C inhibitors because it binds to a different pocket present in both the active and inactive forms of KRAS",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31332011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232209",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Additionally, we show that KRASG13D/+ and KRASG13D/- cells have a distinct metabolic profile characterized by dysregulation of TCA cycle, up-regulation of glycolysis and glutathione metabolism pathway as well as increased glutamine uptake and acetate utilization.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34822010",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308773",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The most prevalent mutations among patients with PC are c.1621A>C (rs3822214) in KIT, c.38G>C (rs112445441) in KRAS and c.733G>A (rs28934575) in TP53 genes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29650325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "KRAS codon 12 mutations in Australian non-small cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9612526",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31309326",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In lung cancers, the mutations concentrate at codon 12 and mostly affect adenocarcinomas (ADCs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20846262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "KRASG12C represents only 11% of all KRAS mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33860195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Most of the mutations were identified in codon 12 in 16 patients (61.5% of all mutations). We identified a novel mutation c.51\u00a0G>A in codon 17, where serine was substituted by arginine (S17R) in four patients. We also identified a very rare mutation, c.91\u00a0G>A, in which glutamic acid was replaced by lysine (E31K) in three patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34369256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similar to the canonical mutants KRAS G12D and KRAS G13D, NIH3T3 cells overexpressing KRAS E31D and KRAS E63K showed altered morphology and were characteristically smaller, rounder, and highly refractile compared with their non-transformed counterparts.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31289513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This system allowed us to rapidly compare the ability of 12 different KRAS mutations (G12A, G12C, G12D, G12F, G12R, G12S, G12V, G13C, G13D, Q61L, Q61R and A146T) to drive pancreatic tumorigenesis in vivo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25065594",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dinucleotide KRAS2 mutations G12F and GG12-13VC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11668624",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29453361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247021",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mutations were detected in 12 tumor samples: five patients with Gly12Val (GGT>GTT), three with Gly12Asp (GGT>GAT), two patients with Gly13Asp (GGC>GAC), one patient with Gly12Ser (GGT>AGT) and one with Gly12Cys (GGT>TGT) mutation in tumor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22329297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The G12D mutation was the most commonly encountered subtype in our cohort (21/50), whereas the G12C mutation was observed in 5 cases, and interestingly, this mutation was only seen in patients with non-small cell lung carcinoma (NSCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709341",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25359494",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "G12C, g12c, KRAS G12C, kras g12c, G12V, g12v, KRAS G12V, kras g12v, G12D, g12d, KRAS G12D, kras g12d, G12A, g12a, KRAS G12A, kras g12a"
}